Soiken Holdings Inc. (2385.T)
JPY 125.0
(-3.85%)
JPY 125.0
(-3.85%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -583.2 Million JPY | -177.51% |
| 2022 | 750.06 Million JPY | -39.03% |
| 2021 | 1.27 Billion JPY | 28.64% |
| 2020 | 948.13 Million JPY | -8.95% |
| 2019 | 1.08 Billion JPY | 16.51% |
| 2018 | 901.32 Million JPY | 142.84% |
| 2017 | 363.95 Million JPY | 27.23% |
| 2016 | 292.65 Million JPY | 34.11% |
| 2015 | 187.06 Million JPY | 2747.93% |
| 2014 | 6 Million JPY | -83.33% |
| 2013 | 45.93 Million JPY | -18.96% |
| 2012 | 110.86 Million JPY | 133.16% |
| 2011 | -166.94 Million JPY | 44.91% |
| 2010 | -297.17 Million JPY | -180.96% |
| 2009 | -97.74 Million JPY | 298.4% |
| 2008 | -193.3 Million JPY | -179.47% |
| 2007 | 113.18 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q4 | -42.71 Million JPY | 56.56% |
| 2023 FY | - JPY | -177.51% |
| 2023 Q1 | -500.89 Million JPY | -750.45% |
| 2023 Q2 | 52.66 Million JPY | 110.51% |
| 2023 Q3 | -98.33 Million JPY | -286.73% |
| 2022 Q1 | 45.94 Million JPY | -83.45% |
| 2022 FY | - JPY | -39.03% |
| 2022 Q4 | -58.89 Million JPY | -113.33% |
| 2022 Q3 | 441.91 Million JPY | 48.01% |
| 2022 Q2 | 298.57 Million JPY | 549.85% |
| 2021 Q3 | 346.92 Million JPY | -33.52% |
| 2021 Q2 | 521.81 Million JPY | 717.98% |
| 2021 Q1 | 63.79 Million JPY | 130.29% |
| 2021 FY | - JPY | 28.64% |
| 2021 Q4 | 277.59 Million JPY | -19.98% |
| 2020 Q2 | 511.97 Million JPY | 378.03% |
| 2020 Q1 | 107.1 Million JPY | -71.84% |
| 2020 Q4 | 27.7 Million JPY | -90.15% |
| 2020 Q3 | 281.09 Million JPY | -45.1% |
| 2020 FY | - JPY | -8.95% |
| 2019 Q4 | 380.3 Million JPY | 4.48% |
| 2019 FY | - JPY | 16.51% |
| 2019 Q1 | -188.67 Million JPY | -183.22% |
| 2019 Q2 | 462.75 Million JPY | 345.27% |
| 2019 Q3 | 363.98 Million JPY | -21.34% |
| 2018 Q4 | 226.7 Million JPY | -37.78% |
| 2018 Q2 | 325.49 Million JPY | 795.04% |
| 2018 FY | - JPY | 142.84% |
| 2018 Q1 | -46.83 Million JPY | -300.79% |
| 2018 Q3 | 364.35 Million JPY | 11.94% |
| 2017 Q3 | 184.34 Million JPY | 3.69% |
| 2017 Q2 | 177.78 Million JPY | 497.95% |
| 2017 FY | - JPY | 27.23% |
| 2017 Q1 | -44.67 Million JPY | -156.36% |
| 2017 Q4 | 23.32 Million JPY | -87.35% |
| 2016 Q4 | 79.27 Million JPY | -52.67% |
| 2016 Q1 | -27.54 Million JPY | -123.66% |
| 2016 FY | - JPY | 34.11% |
| 2016 Q2 | 45.19 Million JPY | 264.09% |
| 2016 Q3 | 167.49 Million JPY | 270.6% |
| 2015 FY | - JPY | 2747.93% |
| 2015 Q4 | 116.41 Million JPY | 8.29% |
| 2015 Q3 | 107.5 Million JPY | 15.34% |
| 2015 Q2 | 93.2 Million JPY | 181.42% |
| 2015 Q1 | -114.47 Million JPY | -244.73% |
| 2014 Q3 | 56.65 Million JPY | -33.95% |
| 2014 FY | - JPY | -83.33% |
| 2014 Q4 | 79.09 Million JPY | 39.61% |
| 2014 Q1 | -231.51 Million JPY | -448.23% |
| 2014 Q2 | 85.77 Million JPY | 137.05% |
| 2013 Q3 | 85.1 Million JPY | -19.97% |
| 2013 Q1 | -121.42 Million JPY | -85.67% |
| 2013 Q2 | 106.34 Million JPY | 187.58% |
| 2013 Q4 | -42.22 Million JPY | -149.62% |
| 2013 FY | - JPY | -18.96% |
| 2012 Q1 | 71.76 Million JPY | 520.26% |
| 2012 Q3 | 10.38 Million JPY | -74.45% |
| 2012 Q2 | 40.64 Million JPY | -43.37% |
| 2012 FY | - JPY | 133.16% |
| 2012 Q4 | -65.39 Million JPY | -729.71% |
| 2011 FY | - JPY | 44.91% |
| 2011 Q4 | -17.07 Million JPY | 35.51% |
| 2011 Q3 | -26.47 Million JPY | 67.97% |
| 2011 Q1 | -65.8 Million JPY | 6.82% |
| 2011 Q2 | -82.65 Million JPY | -25.6% |
| 2010 Q2 | -63.26 Million JPY | 52.01% |
| 2010 Q3 | -44.78 Million JPY | 29.21% |
| 2010 FY | - JPY | -180.96% |
| 2010 Q4 | -70.62 Million JPY | -57.7% |
| 2010 Q1 | -131.81 Million JPY | -116.38% |
| 2009 Q4 | 804.65 Million JPY | 777.18% |
| 2009 FY | - JPY | 298.4% |
| 2009 Q1 | -169.13 Million JPY | -463.88% |
| 2009 Q2 | -133.17 Million JPY | 21.26% |
| 2009 Q3 | -118.82 Million JPY | 10.77% |
| 2008 Q4 | 46.48 Million JPY | 162.89% |
| 2008 FY | - JPY | -179.47% |
| 2008 Q2 | -35.91 Million JPY | 71.32% |
| 2008 Q1 | -125.22 Million JPY | 0.0% |
| 2008 Q3 | -73.91 Million JPY | -105.83% |
| 2007 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 160.871% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -19.477% |
| GNI Group Ltd. | 14.48 Billion JPY | 104.025% |
| Linical Co., Ltd. | 1.24 Billion JPY | 146.76% |
| Trans Genic Inc. | 240.95 Million JPY | 342.042% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 56.986% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | 3.297% |
| AnGes, Inc. | -8.86 Billion JPY | 93.418% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 54.632% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 92.118% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 555.249% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 32.421% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 46.582% |
| CanBas Co., Ltd. | 53.65 Million JPY | 1187.037% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 24.805% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -421.646% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 51.87% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 57.764% |
| PeptiDream Inc. | 7.37 Billion JPY | 107.907% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 69.777% |
| Ribomic Inc. | -1.01 Billion JPY | 42.401% |
| SanBio Company Limited | -4.52 Billion JPY | 87.111% |
| Healios K.K. | -3 Billion JPY | 80.605% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 49.973% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 58.135% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 58.402% |
| StemRIM | -2.03 Billion JPY | 71.299% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 144.641% |
| FunPep Company Limited | -952 Million JPY | 38.739% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 34.38% |
| Stella Pharma Corporation | -723.85 Million JPY | 19.43% |
| TMS Co., Ltd. | -937 Million JPY | 37.758% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 24.786% |
| Cuorips Inc. | -518 Million JPY | -12.588% |
| K Pharma,Inc. | 366.05 Million JPY | 259.321% |
| Takara Bio Inc. | 8.02 Billion JPY | 107.268% |
| ReproCELL Incorporated | 8.24 Million JPY | 7173.451% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 763.201% |
| StemCell Institute Inc. | 534.35 Million JPY | 209.142% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 338.224% |
| CellSeed Inc. | -836.51 Million JPY | 30.282% |